司美格鲁肽减重药正式迎来口服时代,但服药还有这些限制

第一财经
Dec 23, 2025

当地时间12月22日,诺和诺德的重磅GLP-1类药物司美格鲁肽口服版减重药正式获得美国FDA批准。公司表示,该药物将于明年1月初在美国上市。司美格鲁肽也成为全球范围内获得批准的首款用于减重的GLP-1类药物,此前全球都没有用于减重的GLP-1口服片剂获批。当天盘后,诺和诺德美国股价上涨近10%。竞争对手礼来股价下跌超过1%,礼来的口服版GLP-1减重药也已进入美国FDA快速审批阶段,有望于明年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10